4/22
02:11 pm
phvs
Pharvaris (NASDAQ: PHVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.
Low
Report
Pharvaris (NASDAQ: PHVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.
4/15
01:18 pm
phvs
Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Morgan Stanley from $35.00 to $34.00. They now have an "overweight" rating on the stock.
Low
Report
Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Morgan Stanley from $35.00 to $34.00. They now have an "overweight" rating on the stock.
4/12
08:14 am
phvs
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
4/11
01:02 pm
phvs
Pharvaris (NASDAQ: PHVS) had its price target raised by analysts at JMP Securities from $49.00 to $50.00. They now have a "market outperform" rating on the stock.
Low
Report
Pharvaris (NASDAQ: PHVS) had its price target raised by analysts at JMP Securities from $49.00 to $50.00. They now have a "market outperform" rating on the stock.
4/11
10:22 am
phvs
Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.
Low
Report
Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.
4/10
04:17 pm
phvs
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer [Yahoo! Finance]
Low
Report
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer [Yahoo! Finance]
4/10
04:17 pm
phvs
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
4/10
04:10 pm
phvs
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Low
Report
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4/10
04:08 pm
phvs
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
Low
Report
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
4/4
07:03 am
phvs
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference [Yahoo! Finance]
Low
Report
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference [Yahoo! Finance]
4/4
06:50 am
phvs
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
Low
Report
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
3/19
09:31 am
phvs
Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.
Medium
Report
Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.
3/18
07:02 am
phvs
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses [Yahoo! Finance]
Medium
Report
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses [Yahoo! Finance]
3/18
06:50 am
phvs
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
Medium
Report
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
3/6
07:00 am
phvs
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses [Yahoo! Finance]
Medium
Report
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses [Yahoo! Finance]
3/6
06:50 am
phvs
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
Medium
Report
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
3/5
06:50 am
phvs
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
Medium
Report
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
2/22
07:06 am
phvs
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting [Yahoo! Finance]
2/22
06:50 am
phvs
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Low
Report
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
2/16
07:07 am
phvs
Pharvaris Announces Extraordinary Meeting of Shareholders [Yahoo! Finance]
Neutral
Report
Pharvaris Announces Extraordinary Meeting of Shareholders [Yahoo! Finance]
2/16
06:50 am
phvs
Pharvaris Announces Extraordinary Meeting of Shareholders
Neutral
Report
Pharvaris Announces Extraordinary Meeting of Shareholders
2/14
02:13 pm
phvs
Pharvaris (NASDAQ: PHVS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $49.00 price target on the stock.
Medium
Report
Pharvaris (NASDAQ: PHVS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $49.00 price target on the stock.
2/13
06:58 am
phvs
Kalvista pill succeeds in late-stage study for rare swelling disorder [Yahoo! Finance]
Medium
Report
Kalvista pill succeeds in late-stage study for rare swelling disorder [Yahoo! Finance]